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Abstract
Background: Treatment failure has become a significant challenge in patients taking antiretroviral therapy (ART).
The aim of the present study was to identify risk factors for first-line ART failure among patients attending clinical
follow-up.
Methods: A 1:2 matched case-control study (by age, sex, and treatment duration since initiated on ART) was conducted
from June 2015 to July 2017 on adult patients (aged ≥15 years) who were on ART for at least 6 months. Cases were
selected from patients who were switched to second-line ART after first-line ART failure (viral load ≥1000 copies/mL).
Controls were randomly selected from patients on first-line ART with viral load < 50 copies/mL. Data were collected using
an interview questionnaire, reviewing chart and electronic health records and laboratory tests. Multivariate logistic
regression analysis was performed to identify risk factors for treatment failure.
Results: Of the 273 patients who participated in this study, 55% were males. Ninety-one cases were compared with 182
controls. The median age of participants was 40 years and the median duration of treatment since initiated on ART was
69months. Independent risk factors associated with first-line antiretroviral treatment failure were discontinuation of ART
(adjusted odds ratio (AOR) = 9.8, 95% confidence interval (CI): 4.0–23.8), baseline CD4 lymphocyte count ≤50 cells/mm3
(AOR = 3.8, 95% CI: 1.5–9.6) and persistent diarrhea (AOR = 4.4, 95% CI: 1.5–13.2). The risk of ART failure was high and
comparable whether the duration of ART discontinuation was greater or less than 1 month (crude odds ratio (COR) = 6.3
and 8. 5 respectively, p-value < 0.001). Frequent eating of a diet containing wheat or barley (AOR = 2.3, 95% CI: 0.9–5.4)
showed a trend to be a risk factor for first-line ART failure (p-value = 0.064).
Conclusions: Our findings underscore the importance of avoiding ART discontinuation of any duration, early initiation of
ART and diarrhea management to prevent first-line ART failure.
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Background
Worldwide Human Immunodeficiency Virus (HIV)/Ac-
quired Immune Deficiency Syndrome (AIDS) is a major
public health issue. In 2017, over 36.9 million people
were living with HIV/AIDS. The most affected contin-
ent, Africa, had 25.7 million (70%) people with HIV/
AIDS. In Ethiopia, about 710, 000 people were living
with the disease as of 2017 [1]. The global antiretroviral
therapy (ART) coverage increased progressively from 7%
in 2005 to 59% in 2017 [2, 3]. The estimated coverages
in 2017 were 60 and 59% for Africa and Ethiopia,
respectively [1].
Because of this extensive ART scale-up, treatment fail-
ure has become an emerging problem [4, 5]. The preva-
lence of first-line ART failure differs significantly across
countries depending on the criteria (clinical, immuno-
logical or virologic) used for its diagnosis. The viral load
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cut-off points to diagnose treatment failure also vary in
different countries. The first-line ART virologic failure
rate in Africa was 7.1 (95% CI: 5.1–9.1) per 100 patient-
years of follow-up [6]. In Ethiopia, studies reported viro-
logic failure rates ranging from 5.3 to 19% [7–9], and the
percentage of patients switched to second-line ART was
1.5% in 2013 [10]. Switching to second-line ART means
that patients are receiving more toxic medications. As a
result, patients become less adherent, and AIDS progres-
sion will be more rapid, both of which make patient
monitoring expensive [11–14].
Previous studies identified that suboptimal adher-
ence, adverse drug reactions [15, 16], higher pre-
treatment (baseline) HIV viral load level, baseline
World Health Organization (WHO) AIDS stage 3 or
4, CD4 lymphocyte count < 50 cells/mm3, low body
mass index (BMI), drug interactions and dyspepsia as
an important risk factors for treatment failure [17–
22]. A study with a clear distinction between
participants with and without ART failure remains
important to identify predictors of treatment failure.
To our knowledge, most studies from Ethiopia used
clinical and immunologic criteria to assess factors that
influence treatment failure. As immunologic and clin-
ical criteria have low sensitivity and specificity to
identify true ART failure [23], it could be difficult to
identify risk factors based on these two criteria alone.
Therefore, this study aimed to investigate risk factors
for first-line antiretroviral failure using the virologic
(plasma viral load) criteria.
Methods
Study setting
This study was carried out at the ART follow-up clinic
of Asella Hospital, Ethiopia. The hospital gives clinical
service to a total population of about 3.5 million people.
There were 3238 patients with HIV/AIDS (including
those from the surrounding rural areas and nearby
towns) who had an ART follow-up in the hospital of
which 102 (3.2%) patients were on second-line ART.
Study design and participants
A 1:2 matched case-control study (by age, sex and treat-
ment duration since initiated on ART) was conducted
between June 2015 to July 2017 (study period). All adult
HIV-positive patients (aged ≥15 years) who were on
ART for at least 6 months and whose baseline CD4
lymphocyte count and WHO HIV stage details available
using the ART electronic health record of Asella Hos-
pital were our target population. This data ranges from
January 2005 to May 2017, and only patients not died
and had an active follow-up at the time of the study
were included. Ninety-one patients who were receiving
second-line ART were selected as cases. Treatment fail-
ure status for cases was confirmed by two viral load tests
(viral load ≥1000 copies/mL), performed 3 months apart
as per national guideline, before a change of ART regi-
men. Controls were 182 patients with undetectable viral
load (less than 50 copies/mL) who were taking first-line
ART for at least 6 months. Details of the selection
process are described below (Fig. 1).
Fig. 1 The selection process of study participants. (ART = Antiretroviral therapy, VL = viral load)
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For each case, two controls were selected using a lot-
tery method after being matched by age, sex, and dur-
ation on ART. We used the following technique for
selecting controls for each case. For example, for a case
who commenced ART in June 2005, we used an elec-
tronic ART database to find two controls who were also
initiated on ART in June 2005 with similar gender and
within ±5 years of age of the case.
Variables and measures
Sociodemographic and clinical characteristics of partici-
pants were assessed for their possible association with
the outcome variable (ART failure) (Table 1). The vari-
ables measured before ART initiation were baseline CD4
lymphocyte count and WHO HIV stage, whereas all the
other variables were retrospectively measured during pa-
tient follow-up after ART was started.
Duration on ART was defined as the total time (in
months) a patient was on ART since initial enrolment
into ART care excluding the period of interruptions. Dis-
continuation of ART for a patient currently on ART was
defined as having a history of complete stoppage of ART
medications for any duration; whereas missed ART
follow-up meant that a patient missed a drug refill date.
The ART regimen for cases was their first-line ART regi-
men, not their current second-line regimen.
Repeated or persistent diarrhea was defined as ≥2 epi-
sodes of diarrhea or a single episode lasting more than
2 weeks, respectively. We used the term psychiatric ill-
ness in patients who were diagnosed with a disorder
listed in the Diagnostic and Statistical Manual of Mental
Disorders IV [24]. Tuberculosis (TB) co-infection was
defined as an active TB disease requiring a curative ther-
apy with anti-TB medications. Alcohol use was defined
as the use of alcoholic beverages in any amount. A
main-diet constitutes the usual sum of food consumed
by participants in a stable manner for years. Poor drug
absorption was assumed to be present in those patients
who experienced diarrhea (repeated or persistent) and
frequently eat wheat or barely. For variables measuring
co-existing chronic infections, we presumed that these
diseases were either acquired during a similar high-risk
behavior that led to the acquisition of HIV itself (hepa-
titis B virus (HBV), hepatitis C virus (HCV), and syph-
ilis) or acquired early in life (HBV and Helicobacter
pylori (H. pylori) infection).
Data collection tool and procedure
The data collection tools were interview-questionnaire,
electronic ART database, patient chart review and viro-
logic test for selection of controls. In addition, other la-
boratory tests were also performed to detect chronic
carrier state for infections, including HBV, HCV, H.
pylori and Venereal disease research laboratory (VDRL)
tests for both cases and controls.
The questionnaire was first developed in English and
translated into local languages, Oromiffa and Amharic,
and cross-checked for consistency. It was piloted,
modified and validated. Training was provided for the
study team before the start of the project. The research
team included the three investigators, two registered
nurses who assisted patients to complete the question-
naire, five laboratory technicians and an IT professional
to record all the observations into Epi-info software
daily. The investigators continuously monitored the
data collection process throughout the study. Data
completeness was regularly checked, and any missing
data were obtained on the subsequent follow-up of
patients.
Data processing and analysis
Data from Epi-Info was exported to SPSS statistics ver-
sion 23.0. Descriptive statistics were used to present
socio-demographic and clinical characteristics. Bivariate
logistic regression analysis was carried out, and inde-
pendent variables with p-values of ≤0.2 were included in
multivariate logistic regression analysis. Prior to the
multivariate analysis, multicollinearity diagnostics was
performed, and there were no significant interactions be-
tween independent variables. Adjusted odds ratios
(AOR) with 95% confidence intervals (CIs) were used as
an effect measure. A p-value of equal or less than 0.05
was considered as significant. The matching factors (age,
sex and duration of ART) were included in the adjusted
analysis.
Ethics approval
Ethical approval was obtained from the Arsi University
College of Health Sciences Ethics Review Board. Informed
consent was obtained from study participants. Informa-
tion gathered from respondents was treated confidentially,
and the norm of the community was considered and
respected in the process of data collection. Patients with
abnormal findings were referred to the treating physician
and were provided with the appropriate care.
Results
Socio-demographic characteristics of participants
Of all 273 study participants, 55% were males. The me-
dian age of the participants was 40 years. The median
duration of treatment was 69months. Most of the par-
ticipants were Orthodox Christian 187 (69%), married
160 (59%), and literate 234 (86%). Approximately three-
quarters of patients were living in the urban area, and
267 (98%) were employed (Table 1).
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Table 1 Socio-demographic and baseline clinical characteristic of adult HIV-positive patients, Southeast Ethiopia, 2015–2017
Variables Total
(N = 273)
Patients with ART failure (Cases)
(N = 91)
Patients without ART failure (Controls)
(N = 182)
Gender-male 149 (55%) 52 (19%) 97 (36%)
Median age in years (IQR) 40 (11) 39 (10) 40 (12)
Religion
Orthodox Christian 187 (69%) 62 (23%) 125 (46%)
Muslim 160 (21%) 20 (7%) 37 (14%)
Protestant 27 (10%) 9 (3%) 18 (7%)
Others 2 (1%) 0 (0%) 2 (1%)
Marital status
Married 160 (59%) 47 (17%) 113 (41%)
Not married 113 (41%) 44 (16%) 69 (25%)
Family size
≤ 5 family members 217 (80%) 76 (28%) 141 (52%)
> 5 family members 54 (20%) 13 (5%) 41 (15%)
Educational status
Illiterate 39 (14%) 12 (4%) 27 (10%)
Literate 234 (86%) 79 (29%) 155 (57%)
Employment
Employed 267 (98%) 87 (32%) 180 (66%)
Unemployed 6 (2%) 4 (1%) 2 (1%)
Residence area
Rural 67 (25%) 28 (10%) 39 (14%)
Urban 206 (76%) 63 (23%) 143 (52%)
Khat** chewing
Yes 10 (4%) 4 (4%) 6 (3%)
No 263 (96%) 87 (96%) 176 (97%)
Alcohol use
Yes 7 (3%) 1 (1%) 6 (3%)
No 266 (97%) 90 (99%) 176 (97%)
Smoke cigarettes
Yes 6 (2%) 3 (3%) 3 (2%)
No 267 (98%) 88 (97%) 179 (98%)
Main diet
Wheat or barley 40 (15%) 18 (20%) 22 (12%)
Teff 165 (60%) 54 (60%) 111 (61%)
Others 68 (25%) 19 (20%) 49 (27%)
Poor drug absorption
Main diet wheat or barley with diarrhea 3 (1%) 3 (3%) 0 (0%)
Main diet wheat or barley without diarrhea 37 (14%) 15 (16%) 22 (12%)
Duration on ART median in months (IQR) 69 (41) 64 (39) 72 (36)
Baseline CD4 lymphocyte count
< 50 cells/mm3 33 (12%) 20 (22%) 13 (7%)
≥ 50 cells/mm3 240 (88%) 71 (78%) 169 (93%)
Baseline WHO HIV stage
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Patients with ART failure (Cases)
(N = 91)
Patients without ART failure (Controls)
(N = 182)
Stage 1 26 (10%) 8 (9%) 18 (10%)
Stage 2 93 (34%) 22 (24%) 71 (39%)
Stage 3 140 (51%) 52 (57%) 88 (48%)
Stage 4 14 (5%) 9 (10%) 5 (3%)
ART regimen
AZT based 130 (48%) 57 (63%) 96 (53%)
TDF based 143 (52%) 34 (37%) 86 (47%)
TB treatment while taking ART
Never 231 (85%) 58 (64%) 173 (95%)
Once 33 (12%) 26 (28%) 7 (4%)
Two times 8 (3%) 6 (7%) 2 (1%)
Three or more 1 (0%) 1 (1%) 0 (0%)
Never discontinued ART 212 (78%) 49 (54%) 163 (90%)
Discontinued ART (by duration) 61 (22%) 42 (46%) 19 (10%)
< 1month 32 (12%) 23 (25%) 9 (5%)
> 1month 29 (10%) 19 (21%) 10 (5%)
Missed ART follow-up
Never 233 (85%) 70 (77%) 163 (89.5%)
Sometimes 32 (12%) 14 (15%) 18 (10%)
Often 8 (3%) 7 (8%) 1 (0.5%)
Repeated or persistent diarrhea
Yes 24 (9%) 16 (18%) 8 (4%)
No 249 (91%) 75 (82%) 174 (96%)
Psychiatric illness
Yes 10 (4%) 6 (7%) 4 (2%)
No 263 (96%) 85 (93%) 178 (98%)
Dyspepsia
Yes 82 (30%) 31 (34%) 51 (28%)
No 191 (70%) 60 (66%) 131 (72%)
Diabetic
Yes 1 (0.4%) 1 (1%) 0 (0%)
No 272 (99.6%) 90 (99%) 182 (100%)
Hypertensive
Yes 3 (1%) 0 (0%) 3 (2%)
No 270 (99%) 91 (100%) 179 (98%)
Stool H. pylori antigen positive
Yes 64 (23%) 18 (20%) 46 (25%)
No 209 (77%) 73 (80%) 136 (75%)
HBsAg positive
Yes 12 (4%) 3 (3%) 9 (5%)
No 261 (96%) 88 (97%) 173 (95%)
Anti-HCV positive
Yes 5 (2%) 1 (1%) 4 (2%)
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When we compare the characteristics of cases with
controls in terms of age, sex and duration of ART; they
were roughly comparable in a 1:2 ratio. Compared with
controls, cases were six times more affected with active
tuberculosis and four times more likely to have persist-
ent diarrhea (Tables 1 and 2).
Discussion
This study identified discontinuation of ART, baseline
CD4 lymphocyte count ≤50 cells/mm3 and persistent
diarrhea as independent factors for first-line ART failure.
The risk of ART failure was high and comparable
whether the duration of ART discontinuation was




Patients with ART failure (Cases)
(N = 91)
Patients without ART failure (Controls)
(N = 182)
No 268 (98%) 90 (99%) 174 (96%)
VRDL positive
Yes 56 (20%) 13 (14%) 43 (24%)
No 217 (80%) 78 (86%) 139 (76%)
Note: ART: Antiretroviral Therapy; AZT: Azidothymidine (Zidovudine); HCV: Hepatitis C virus; H. pylori: Helicobacter pylori; HBsAg: Hepatitis B surface antigen; IQR:
interquartile range; TDF: Tenofovir; TB: tuberculosis; VDRL: Venereal disease research laboratory; WHO: World Health Organization. *Teff (Eragrostis tef) is a gluten-
free cereal traditionally grown in Ethiopia [25]. **Khat (Catha edulis) is a plant native to the Horn of Africa and the Arabian Peninsula which contains psychoactive
substances that have a high abuse potential [26]
Table 2 Risk factors for ART failure in adult HIV-positive patients, Southeast Ethiopia, 2015–2017
Variables Bivariate analysis Multivariate analysis
COR 95% CI P-value AOR 95% CI P-value
Illiterate 0.9 0.4–1.8 0.714
Small family ≤5 1.5 0.8–2.8 0.245
Residence in rural area 1.6 0.9–2.9 0.092 1.4 0.6–2.9 0.396
Unemployed 4.1 0.7–23 0.105 1.5 0.1–27.2 0.775
Unmarried 1.5 0.9–2.6 0.100 1.4 0.7–2.7 0.379
Alcohol 3.1 0.4–25.9 0.303
smoking cigarette 2.0 0.4–10.3 0.390
Khat** chewing 1.3 0.4–4.9 0.650
Main diet wheat or barley vs other food 1.8 0.9–3.5 0.093 2.3 0.9–5.4 0.064
Main diet teff vs wheat or barley 0.6 0.3–1.2 0.147
Baseline CD4 lymphocyte count ≤50 cells/mm3 3.7 1.7–7.8 < 0.001 3.8 1.5–9.6 0.005
Baseline WHO stage 4 3.9 1.3–12.0 0.018 0.3 0.1–1.4 0.138
Discontinuation of ART 7.4 3.9–13.8 < 0.001 9.8 4.0–23.8 < 0.001
< 1month 8.5 3.7–19.6 < 0.001
> 1month 6.3 2.8–14.5 < 0.001
AZT based regimen 1.5 0.9–2.5 0.121 1.3 0.7–2.6 0.392
Missed ART follow-up 2.6 1.3–5.1 0.007 1.6 0.6–4.8 0.362
Repeated or persistent diarrhea 4.6 1.9–11.3 < 0.001 4.4 1.5–13.2 0.007
Dyspepsia 1.3 0.8–2.3 0.305
Psychiatric illness 3.1 0.9–11.4 0.082 0.6 0.3–1.5 0.272
Anti-HCV positive 2.0 0.2–18.4 0.531
HBsAg positive 1.5 0.04–5.8 0.534
H. pylori antigen positive 0.7 0.4–1.3 0.314
VDRL positive 0.5 0.3_1.1 0.074 0.6 0.3–1.5 0.272
Note: ART: Antiretroviral Therapy; AZT: Azidothymidine (Zidovudine); CI: Confidence interval; COR: Crude odds ratio; HCV: Hepatitis C virus; H. pylori: Helicobacter
pylori; HBsAg: Hepatitis B surface antigen; VDRL: Venereal disease research laboratory; WHO: World Health Organization. *Teff (Eragrostis tef) is a gluten-free cereal
traditionally grown in Ethiopia [25]. ** Khat (Catha edulis) is a plant native to the Horn of Africa and the Arabian Peninsula and contains psychoactive substances
that have a high abuse potential [26]
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greater or less than 1 month. Frequent eating of a diet
made of wheat or barely showed a trend of statistically
significant association with first-line ART failure.
Patients who did experience first-line ART failure were
nearly 10 times more likely to have a history of total
ART discontinuation (AOR = 9.8, 95% CI: 4.0–23.8) than
those who did not. The risk of ART failure in patients
who discontinued ART for more than 1 month (COR =
6.3, 95% CI: 2.8–14.5) was comparable with those who
discontinued it for less than 1 month (COR = 8.5, 95%
CI: 3.7–19.6). The association between ART failure and
drug discontinuation was also significant in other studies
conducted in a similar setting. Comparable findings were
reported by case-control studies from Zimbabwe (AOR =
5.1, 95% CI 2.8–10.0) [19], Tanzania (AOR = 12.0, 95%
CI 2.1–69.3) [27] and the northern part of Ethiopia
(AOR = 15.80, 95% CI: 6.9–36.5) [28].
Patients who were initiated on ART at an advanced
stage of HIV/AIDS (baseline CD4 lymphocyte count ≤50
cells/mm3) were four times more likely to experience
first-line ART failure (AOR = 3.8, 95% CI: 1.5–9.6) in this
study. Several studies reported that starting ART late in
patients with advanced immunosuppression is associated
with antiretroviral treatment failure [17, 29–33].
Persistent diarrhea was also found to be an independ-
ent predictor of ART failure (AOR = 4.4, 95% CI: 1.5–
13.2) as documented in other studies [34, 35]. Poor
absorption of ART medications associated with a general
malabsorption state could occur in patients with persist-
ent diarrhea. However, this finding could be an overesti-
mation as persistent diarrhea could be a manifestation of
ART failure itself with disproportionately more diarrheal
cases among the cases group.
Furthermore, frequent eating of wheat or barley-based
meal (AOR = 2.3, 95% CI: 0.9–5.4) showed a trend to be a
risk factor for first-line ART failure (p-value < 0.064) com-
pared with other food. It is important to note that wheat
and barley are gluten-containing foods, and both foods
accelerate gastrointestinal transit [36, 37]. Compared to
barley and wheat, frequent eating of teff, which is a
gluten-free staple grain of Ethiopian cuisine [25], showed
a decreased odds ratio for ART failure (COR = 0.6, 95%
CI: 0.3–1.2). To our knowledge, there are no previous
studies that documented frequent eating of wheat and
barley-based diet as a risk factor for first-line ART failure,
and further studies with larger sample size are required
before generalizing.
Our study has several limitations. Most of the
independent variables were self-reported. Therefore,
memory bias and imperfect temporal precedence could
have under or overestimated our results. The smaller
study population and sensitivity and specificity of labora-
tory tests might also have affected the accuracy of our
findings.
Conclusions
Discontinuation of ART drugs, persistent diarrhea and
baseline CD4 lymphocyte count ≤50 cells/mm3 were
strongly associated with first-line ART failure. Our find-
ings underscore the importance of avoiding ART discon-
tinuation of any duration to prevent treatment failure.
Wheat or barley as the main diet could be a possible
cause for ART failure; however, further studies are
needed.
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